Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib versus placebo in previously treated advanced predominantly non-squamous NSCLC
NL-OMON37229Phase 3Active, not recruiting
- Sponsor
- Bayer
- Start
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Sorafenib plus best supportive care with Placebo plus best supportive care (2 arms). Primary endpoint: overall survival. Started Aug 2009; status: active, not recruiting.
02
Drugs
sorafenib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON37229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37229.